Phase 1 COPD Trial, Recruiting NCT07288554 Sponsor: Bambusa Therapeutics Condition: COPD
Back to Copd

Phase 1 COPD Trial, Recruiting

NCT07288554
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years (for the healthy volunteer part) or 35 to 75 years (for the patient part), with a body weight no higher than 120 kg and a body mass index between 18 and 32
  • Women of childbearing potential who have a negative pregnancy test result
  • People who do not drink alcohol in the 24 hours before each study visit
  • People who are non-smokers, ex-smokers, or current smokers who smoke no more than 5 cigarettes per day
  • People who use adequate contraception, if they are men or women who could potentially have children
  • People with no significant medical conditions or serious medical history
  • For the patient part only: people who have a confirmed diagnosis of COPD, with specific lung function test results showing an FEV1/FVC ratio below 0.70 after using a bronchodilator, and an FEV1 result between 50% and 80% of the expected value (confirm with trial site)

Who may not be able to join:

  • People who test positive for HIV, hepatitis B, or hepatitis C
  • People who have immune system disorders, autoimmune diseases, cancer, or a history of conditions that increase the risk of infections
  • People with a history of major problems affecting metabolism, skin, liver, kidneys, blood, or other serious health conditions
  • People with significantly abnormal blood test results, including problems with blood cell counts, liver enzyme levels, or kidney function
  • People who test positive for drugs or alcohol, or who have abnormal vital signs, at the screening visit or the day before the study begins
  • People with abnormal heart trace (ECG) results
  • People with a history of drug or alcohol misuse in the past two years
  • People with a history of severe allergic reactions or serious sensitivity to medications
  • For the patient part only: people who currently have another significant lung disease
  • For the patient part only: people who have serious or unstable heart or cardiovascular conditions
  • For the patient part only: people who have had a significant infection recently
  • For the patient part only: people who are unable to perform breathing tests (spirometry)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18001322760

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Bambusa Therapeutics
Registry
ClinicalTrials.gov
Start date
5 September 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of participants with adverse events following single and multiple administration of BBT002; Number of participants with change in Laboratory assessments; Number of participants with change in vital sign measurements following dose administration.; Number of participants with change in physical examination following dose administration.; Number of participants with change in 12-lead ECG readings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov